Sequent Scientific Limited has officially completed its transformation to Viyash Scientific Limited, marking a significant corporate milestone with the formal approval from regulatory authorities. The name change became effective from January 8, 2026, following the receipt of necessary approvals from the Registrar of Companies.

Regulatory Approval and Timeline

The company received the crucial approval from the Registrar of Companies (ROC) for the name change on January 8, 2026. The ROC issued a fresh Certificate of Incorporation on the same date, which was subsequently received by the company on January 9, 2026. This regulatory approval represents the final step in the corporate name change process that began several months earlier.

Shareholder Approval Process

The name change proposal received formal approval from shareholders through a special resolution passed via postal ballot on December 28, 2025. This democratic process ensured that the corporate transformation had the backing of the company's ownership base before proceeding with regulatory formalities.

Corporate Identity Details

The company's Corporate Identification Number (CIN) remains unchanged at L99999TS1985PLC196357, ensuring continuity in regulatory identification. According to the Certificate of Incorporation, the company was originally incorporated as Visistha Trades and Finance Limited before becoming Sequent Scientific Limited, and now operates as Viyash Scientific Limited.

Regulatory Compliance and Next Steps

Viyash Scientific Limited has informed both BSE Limited and National Stock Exchange of India Limited about the completed name change under Regulation 30 of the SEBI Listing Regulations. The company is currently in the process of filing required documents with the stock exchanges for necessary updates to trading systems and records.

Legal Requirements and Obligations

As per regulatory requirements under Section 12 of the Companies Act, Viyash Scientific Limited must display its former name "Sequent Scientific Limited" alongside the new name for a period of two years at all places where the company is required to display its name. This ensures transparency and continuity for stakeholders during the transition period.

The name change does not affect the rights and liabilities of stakeholders, maintaining all existing contractual and legal obligations under the new corporate identity. The company continues to operate from its registered office in Hyderabad and maintains its operational office in Thane, Maharashtra.

Sequent Scientific Limited has announced the allotment of 1,00,000 equity shares under its Employee Stock Option Plan 2020 (SeQuent ESOP 2020) scheme. The Nomination and Remuneration Committee approved this allotment through a resolution passed by circulation on December 30, 2025.

ESOP Allotment Details

The company has issued equity shares to eligible employees under the following terms:

The newly allotted equity shares will rank pari passu in all respects with the existing equity shares of the company, ensuring equal rights and privileges for all shareholders.

Impact on Share Capital

The allotment has resulted in an increase in the company's issued and paid-up equity share capital:

The increase represents a marginal expansion of 0.023% in the total number of outstanding equity shares.

Corporate Governance

The allotment was executed following proper corporate governance procedures, with the Nomination and Remuneration Committee exercising its authority to approve the issuance. Company Secretary and Compliance Officer Yoshita Vora signed the regulatory filing, ensuring compliance with stock exchange requirements.

The company has duly informed both BSE Limited (Scrip code: 512529) and National Stock Exchange of India Limited (Symbol: SEQUENT) about this corporate action for their records and necessary market updates.